A phase 1 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV-1 gag DNA vaccine [HIV DNA vaccine] administered alone or with escalating doses of IL-12 DNA or IL-15 DNA molecular adjuvants to HIV-1 positive adults receiving stable HAART [highly active antiretroviral therapy]

Trial Profile

A phase 1 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV-1 gag DNA vaccine [HIV DNA vaccine] administered alone or with escalating doses of IL-12 DNA or IL-15 DNA molecular adjuvants to HIV-1 positive adults receiving stable HAART [highly active antiretroviral therapy]

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2007

At a glance

  • Drugs HIV DNA vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Aug 2007 Status change
    • 31 May 2007 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top